Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
3.440
-0.090 (-2.55%)
Aug 14, 2026, 4:00 PM EDT - Market closed

Galectin Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-15.62-20.09-42.43-38.07-38.35-30.18
Net Income
-28.03-30.97-47.2-44.81-38.87-30.7
Earnings Per Share
-0.43-0.48-0.76-0.74-0.65-0.52
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
13.2717.7215.1225.6618.5939.65
Total Debt
143.96137.72106.6672.8139.9329.06
Net Cash (Debt)
-130.69-120-91.54-47.15-21.3410.59
Net Cash Growth
------60.90%
Net Cash Per Share
-2.01-1.88-1.47-0.78-0.360.18

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-15.89-23.88-41.77-32.97-31.06-24.31
Free Cash Flow
-15.89-23.88-41.77-32.97-31.06-24.31
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.